Pay in 4 interest-free payments of $5.16 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
Compare your options on WithPower Clinical Trials: Where Next-Gen Options Are Headed CYB003 (Deuterated Psilocybin Analog, Cybin Inc.) Mechanism: 5-HT2A receptor agonist (serotoninsame highway, different car) Results: 79% response rate at 3 weeks, no chronic sexual side effects, weight gain, or sedation NCT05385783 Osavampator (AMPA-PAM, Neurocrine) Mechanism: Enhances brain glutamate signaling (not serotonin) Results: Significant symptom reduction, low rates of sexual or metabolic side effects Phase 2 data Dextromethorphan-Bupropion (Auvelity) Mechanism: NMDA antagonist/sigma-1 agonist (plus NDRI) Results: Rapid effect (1 week), 54% response at 6 weeks, sexual dysfunction in only 2-3% GEMINI trial S47445 (AMPA-PAM, Servier) Mechanism: AMPA positive allosteric modulator Results: Favorable side effect profile (low sedation/sexual issues) Phase 2 data Trial participation: Typically free care/meds, lots of monitoring, sometimes a placebo arm
The future of cigarette packaging lies in developing innovative materials that are both sustainable and functional
Our partner hitnspin-casino.ch/fr official website of HitnSpin Casino in Switzerland, said: Une exprience immersive et innovante attend les joueurs sur hitnspin casino
LERMAN: I see that, but theyre so different
